{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T12:28:37Z","timestamp":1786364917653,"version":"build-2736575974"},"reference-count":39,"publisher":"BMJ","issue":"3","license":[{"start":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T00:00:00Z","timestamp":1786320000000},"content-version":"unspecified","delay-in-days":40,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["POS-T3-AN"],"award-info":[{"award-number":["POS-T3-AN"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2026,7,30]]},"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Rheumatoid arthritis (RA) is associated with inflammation-driven hypercoagulability and increased venous thromboembolic risk. Post hoc analyses of safety trials have raised concerns regarding a potential differential thrombotic risk with Janus kinase inhibitors (JAKi) compared with tumour necrosis factor inhibitors (TNFi).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To compare viscoelastic coagulation profiles and platelet reactivity in patients with RA treated with JAKi or TNFi, and in healthy controls (HC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this single-centre observational study, patients with RA with stable JAKi or TNFi therapy (&gt;3 months) underwent whole-blood rotational thromboelastometry (ROTEM) and impedance aggregometry (MULTIPLATE). The primary outcomes were evaluation of: (a) whole-blood thrombogenic potential and (b) platelet reactivity. Multivariable linear regression adjusted for age, body mass index, ln-transformed Simple Disease Activity Index, treatment group and ln-transformed prednisone dose.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Sixty-one patients with RA (30 JAKi, 31 TNFi) and 34 HC were included. Compared with HC, patients with RA exhibited significantly higher maximum clot firmness (MCF) across all ROTEM assays (INTEM 63.4\u00b14.0\u2009vs 57.2\u00b14.1\u2009mm; EXTEM 66.2\u00b14.1\u2009vs 55.9\u00b14.7\u2009mm; FIBTEM 15.7\u00b13.6\u2009vs 12.4\u00b13.7\u2009mm; all p&lt;0.001) and enhanced platelet aggregation (all p&lt;0.001). In multivariable analyses, JAKi therapy (vs TNFi) was independently associated with higher EXTEM MCF (\u03b2=2.32, 95%\u2009CI 0.42 to 4.23; p=0.018) and FIBTEM MCF (\u03b2=1.72, 95%\u2009CI 0.07 to 3.37; p=0.041). Prednisone dose independently predicted INTEM and EXTEM MCF, while SDAI independently predicted ADP-induced aggregation (\u03b2=11.34, 95%\u2009CI 4.31 to 18.37; p=0.002).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>RA is characterised by enhanced clot firmness and platelet reactivity. JAKi therapy was independently associated with higher viscoelastic clot strength compared with TNFi, while inflammatory burden and glucocorticoid exposure were key determinants of prothrombotic signatures.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/rmdopen-2026-006960","type":"journal-article","created":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T11:35:18Z","timestamp":1786361718000},"page":"e006960","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Whole-blood coagulation and platelet dynamics identify differential prothrombotic states in patients with rheumatoid arthritis treated with JAK or TNF-\u0251 inhibitors"],"prefix":"10.1136","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9355-7673","authenticated-orcid":false,"given":"Alessandro","family":"Giollo","sequence":"first","affiliation":[{"name":"Rheumatology Unit, Department of Medicine (DIMED), University of Padova, Padova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Di Luozzo","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, Department of Medicine (DIMED), University of Padova, Padova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariangela","family":"Salvato","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, Department of Medicine (DIMED), University of Padova, Padova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiren","family":"Khalid","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, Department of Medicine (DIMED), University of Padova, Padova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"D\u2019Andrea","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, Department of Medicine (DIMED), University of Padova, Padova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Benetti","sequence":"additional","affiliation":[{"name":"Internal Medicine & Thrombotic and Haemorrhagic Diseases Unit, Department of Medicine (DIMED), University of Padova, Padova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Sam\u00e0","sequence":"additional","affiliation":[{"name":"Internal Medicine & Thrombotic and Haemorrhagic Diseases Unit, Department of Medicine (DIMED), University of Padova, Padova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9683-8873","authenticated-orcid":false,"given":"Roberta","family":"Ramonda","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, Department of Medicine (DIMED), University of Padova, Padova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Simioni","sequence":"additional","affiliation":[{"name":"Internal Medicine & Thrombotic and Haemorrhagic Diseases Unit, Department of Medicine (DIMED), University of Padova, Padova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Spiezia","sequence":"additional","affiliation":[{"name":"Internal Medicine & Thrombotic and Haemorrhagic Diseases Unit, Department of Medicine (DIMED), University of Padova, Padova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,8,10]]},"reference":[{"key":"2026081004351303000_12.3.e006960.1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204021"},{"key":"2026081004351303000_12.3.e006960.2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-218419"},{"key":"2026081004351303000_12.3.e006960.3","doi-asserted-by":"publisher","DOI":"10.1038\/s41569-021-00552-1"},{"key":"2026081004351303000_12.3.e006960.4","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-021-02546-3","article-title":"Tumour necrosis factor inhibitors reduce aortic stiffness progression in patients with long-standing rheumatoid arthritis","volume":"23","author":"Giollo","year":"2021","journal-title":"Arthritis Res Ther"},{"key":"2026081004351303000_12.3.e006960.5","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-003912","article-title":"Risk of extended major adverse cardiovascular event endpoints with tofacitinib versus TNF inhibitors in patients with rheumatoid arthritis: a post hoc analysis of a phase 3b\/4 randomised safety study","volume":"10","author":"Buch","year":"2024","journal-title":"RMD Open"},{"key":"2026081004351303000_12.3.e006960.6","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1002\/art.42846","article-title":"Risk of venous thromboembolism with tofacitinib versus tumor necrosis factor inhibitors in cardiovascular risk-enriched rheumatoid arthritis patients","volume":"76","author":"Charles-Schoeman","year":"2024","journal-title":"Arthritis Rheumatol"},{"key":"2026081004351303000_12.3.e006960.7","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2022-002571","article-title":"Biomarkers to predict risk of venous thromboembolism in patients with rheumatoid arthritis receiving tofacitinib or tumour necrosis factor inhibitors","volume":"8","author":"Weitz","year":"2022","journal-title":"RMD Open"},{"key":"2026081004351303000_12.3.e006960.8","doi-asserted-by":"crossref","first-page":"e166","DOI":"10.1097\/RHU.0000000000002136","article-title":"Comparative analysis of coagulation activation in rheumatoid arthritis patients treated with TNF inhibitors versus JAK inhibitors","volume":"30","author":"Hansildaar","year":"2024","journal-title":"J Clin Rheumatol"},{"key":"2026081004351303000_12.3.e006960.9","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1111\/trf.16073","article-title":"The strengths and weaknesses of viscoelastic testing compared to traditional coagulation testing","volume":"60","author":"Cohen","year":"2020","journal-title":"Transfusion"},{"key":"2026081004351303000_12.3.e006960.10","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23599"},{"key":"2026081004351303000_12.3.e006960.11","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9082636","article-title":"Advances in platelet function testing\u2014light transmission aggregometry and beyond","volume":"9","author":"Le Blanc","year":"2020","journal-title":"J Clin Med"},{"key":"2026081004351303000_12.3.e006960.12","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-018-4134-y"},{"key":"2026081004351303000_12.3.e006960.13","doi-asserted-by":"crossref","first-page":"298","DOI":"10.15403\/jgld-4810","article-title":"Rotational thromboelastometry coagulation parameters (ROTEM\u00ae) may be discriminative for active inflammatory bowel disease: a prospective observational study","volume":"32","author":"Meianu","year":"2023","journal-title":"J Gastrointestin Liver Dis"},{"key":"2026081004351303000_12.3.e006960.14","first-page":"250","article-title":"ABO blood groups and the risk of venous thrombosis in patients with inherited thrombophilia","volume":"11","author":"Spiezia","year":"2013","journal-title":"Blood Transfus Trasfus Sangue"},{"key":"2026081004351303000_12.3.e006960.15","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2024.1386733","article-title":"Cryptogenic ischemic stroke in cardiac transthyretin amyloidosis and sinus rhythm: a case report","volume":"11","author":"Napolitano","year":"2024","journal-title":"Front Cardiovasc Med"},{"key":"2026081004351303000_12.3.e006960.16","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.thromres.2015.01.003","article-title":"Hypercoagulability detected by whole blood thromboelastometry (ROTEM\u00ae) and impedance aggregometry (MULTIPLATE\u00ae) in obese patients","volume":"135","author":"Campello","year":"2015","journal-title":"Thromb Res"},{"key":"2026081004351303000_12.3.e006960.17","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.ijcard.2017.01.072","article-title":"Traditional cardiovascular risk factors or inflammation: which factors accelerate atherosclerosis in arthritis patients?","volume":"236","author":"Dalbeni","year":"2017","journal-title":"Int J Cardiol"},{"key":"2026081004351303000_12.3.e006960.18","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1038\/s41440-020-0441-1","article-title":"Traditional cardiovascular risk factors and residual disease activity are associated with atherosclerosis progression in rheumatoid arthritis patients","volume":"43","author":"Dalbeni","year":"2020","journal-title":"Hypertens Res"},{"key":"2026081004351303000_12.3.e006960.19","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-203380"},{"key":"2026081004351303000_12.3.e006960.20","doi-asserted-by":"publisher","DOI":"10.1016\/S0008-6363(02)00857-X"},{"key":"2026081004351303000_12.3.e006960.21","first-page":"468","article-title":"Tofacitinib attenuates IL-6-mediated endothelial tissue factor induction in vitro without affecting platelet aggregation in vivo: mechanistic insights into cardiovascular risk in rheumatoid arthritis","volume":"44","author":"Cimmino","year":"2026","journal-title":"Clin Exp Rheumatol"},{"key":"2026081004351303000_12.3.e006960.22","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.ard.2025.09.002","article-title":"Augmentation of immunothrombosis as a key mechanism underlying JAK inhibition associated hypercoagulability in rheumatoid arthritis","volume":"85","author":"David","year":"2026","journal-title":"Ann Rheum Dis"},{"key":"2026081004351303000_12.3.e006960.23","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223050"},{"key":"2026081004351303000_12.3.e006960.24","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s40744-022-00505-1","article-title":"Evaluation of VTE, MACE, and serious infections among patients with RA treated with baricitinib compared to TNFi: a multi-database study of patients in routine care using disease registries and claims databases","volume":"10","author":"Salinas","year":"2023","journal-title":"Rheumatol Ther"},{"key":"2026081004351303000_12.3.e006960.25","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.jcrc.2020.09.034","article-title":"Are thromboelastometric and thromboelastographic parameters associated with mortality in septic patients? A systematic review and meta-analysis","volume":"61","author":"Boscolo","year":"2021","journal-title":"J Crit Care"},{"key":"2026081004351303000_12.3.e006960.26","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.thromres.2023.05.010","article-title":"Coagulation profiles in patients with sepsis\/septic shock identify mixed hypo-hypercoagulation patterns based on rotational thromboelastometry: A prospective observational study","volume":"227","author":"Bui-Thi","year":"2023","journal-title":"Thromb Res"},{"key":"2026081004351303000_12.3.e006960.27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcrc.2017.09.183"},{"key":"2026081004351303000_12.3.e006960.28","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.2106\/JBJS.23.00532","article-title":"A pilot observational study evaluating the diagnostic capacity of rotational thromboelastometry in periprosthetic joint infections","volume":"105","author":"Tsantes","year":"2023","journal-title":"J Bone Joint Surg Am"},{"key":"2026081004351303000_12.3.e006960.29","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.thromres.2023.12.009","article-title":"Whole blood viscoelastic testing profile and mortality in patients hospitalized with acute COVID-19 pneumonia: A systematic review and meta-analysis","volume":"234","author":"Spiezia","year":"2024","journal-title":"Thromb Res"},{"key":"2026081004351303000_12.3.e006960.30","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1007\/s10067-013-2368-2","article-title":"The role of hemostatic mechanisms in the development of thrombosis in Behcet\u2019s disease: an analysis by modified rotation thromboelastogram (ROTEM)","volume":"32","author":"Ya\u015far Bilge","year":"2013","journal-title":"Clin Rheumatol"},{"key":"2026081004351303000_12.3.e006960.31","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1016\/j.ard.2025.03.014","article-title":"Janus kinase inhibitors enhance prostanoid biosynthesis in human whole blood in vitro: implications for cardiovascular side effects and prevention strategies","volume":"84","author":"Alabbasi","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"2026081004351303000_12.3.e006960.32","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1055\/s-0040-1722270","article-title":"Use of glucocorticoids and risk of venous thromboembolism: a narrative review","volume":"47","author":"Simion","year":"2021","journal-title":"Semin Thromb Hemost"},{"key":"2026081004351303000_12.3.e006960.33","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1093\/rheumatology\/keae077","article-title":"Very-low-dose glucocorticoid therapy in rheumatoid arthritis: impact of b\/tsDMARDs initiation timing on glucocorticoid withdrawal","volume":"64","author":"Giollo","year":"2025","journal-title":"Rheumatology"},{"key":"2026081004351303000_12.3.e006960.34","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223358"},{"key":"2026081004351303000_12.3.e006960.35","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-010-1446-x"},{"key":"2026081004351303000_12.3.e006960.36","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-015-0665-7","article-title":"Anti-citrullinated protein antibodies contribute to platelet activation in rheumatoid arthritis","volume":"17","author":"Habets","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"2026081004351303000_12.3.e006960.37","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.977828","article-title":"Platelet signaling at the nexus of innate immunity and rheumatoid arthritis","volume":"13","author":"Jiang","year":"2022","journal-title":"Front Immunol"},{"key":"2026081004351303000_12.3.e006960.38","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kep377"},{"key":"2026081004351303000_12.3.e006960.39","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-023-00834-4"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2026-006960","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T11:35:21Z","timestamp":1786361721000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2026-006960"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":39,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,8,10]]},"published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10.1136\/rmdopen-2026-006960"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2026-006960","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]}}}